View Exam | PowerPak

1. Which of the following BEST describes the mechanism of action of ipilimumab?

A. It activates the immune system by binding to CTLA-4 and blocking the interaction of CTLA-4 with its ligands. B. It binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing the inhibition of the immune response. C. It targets the epidermal growth factor receptor and disrupts tumor cell activity. D. It increases the expression of PD-L1, thus increasing antitumor activity.

2. DG is a 55-year-old woman recently diagnosed with advanced non-small cell lung cancer. She tolerated initial platinum-based chemotherapy, but disease progression was detected at the next follow-up evaluation. Genomic assays revealed DG has wildtype EGFR and wildtype ALK. Which of the following is MOST appropriate for DG?

A. Bevacizumab combined with chemotherapy B. Ipilimumab C. Erlotinib D. Nivolumab

3. KD is a 57-year old man with metastatic melanoma who began treatment with nivolumab. After 6 weeks of therapy, his computed tomography scan that showed an increase in the size of his tumor by 50% (the sum of the longest diameter for target lesions). Which of the following is MOST appropriate for KD?

A. Continue the same therapy and perform another scan in 6 weeks B. Discontinue nivolumab and switch to a different PD1 inhibitor C. Discontinue nivolumab and switch to dacarbazine D. Discontinue nivolumab and switch to biochemotherapy

4. FT is a 60-year-old woman with metastatic melanoma who began treatment with pembrolizumab. After 10 weeks of therapy, she developed severe (grade 3) colitis. Which of the following treatment strategies would you recommend next for FT?

A. Hold therapy only B. Hold therapy and initiate steroid therapy C. Permanently discontinue her treatment D. Discontinue her treatment and switch to nivolumab

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following BEST describes the mechanism of action of ipilimumab?

4. FT is a 60-year-old woman with metastatic melanoma who began treatment with pembrolizumab. After 10 weeks of therapy, she developed severe (grade 3) colitis. Which of the following treatment strategies would you recommend next for FT?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following BEST describes the mechanism of action of ipilimumab?

4. FT is a 60-year-old woman with metastatic melanoma who began treatment with pembrolizumab. After 10 weeks of therapy, she developed severe (grade 3) colitis. Which of the following treatment strategies would you recommend next for FT?

« Return to Activity

Customers who Purchased
this Activity also Purchased